Literature DB >> 22427549

Structure/function studies and the effects of memantine in monkeys with experimental glaucoma.

B'ann T Gabelt1, Carol A Rasmussen, Ozan Y Tektas, Charlene B Y Kim, John C Peterson, T Michael Nork, James N Ver Hoeve, Elke Lütjen-Drecoll, Paul L Kaufman.   

Abstract

Purpose. The scanning laser polarimetry with variable corneal compensation (GDx VCC) methodology was established and verified in monkeys with experimental glaucoma (ExpG). Terminal GDx parameters were correlated with axon counts and electrophysiologic measures. The effects of memantine on these parameters were investigated. Methods. ExpG was induced in monkeys and intraocular pressure monitored weekly. Some monkeys received memantine in their diet before and after ExpG induction (1-10 months). GDx VCC scans, stereophotographs, and multifocal visual evoked potential (mfVEP) data were collected at baseline and every 6 to 8 weeks until euthanasia. Optic nerves were prepared for axon counting and other morphologic analysis. Results. There was no difference in IOP elevation exposure between memantine-treated and no-memantine-treated monkeys. The percentage of the optic nerve area composed of connective tissue septa was significantly greater in ExpG eyes than in Fellow eyes. There was a strong positive correlation between axon counts and terminal GDx parameter measures. Animals not receiving memantine exhibited significantly lower mfVEP amplitudes in ExpG eyes compared with the ipsilateral baseline or the final value in the Fellow eye. ExpG eyes from memantine-treated animals had higher overall mean amplitudes that were not significantly different relative to the ipsilateral baseline and final amplitudes in the Fellow eye. Conclusions. The authors' studies confirm that GDx VCC can be utilized in monkey ExpG studies to detect early retinal structural changes and that these changes are highly correlated with optic nerve axon counts. These structural changes may or may not lead to central functional changes as shown by the mfVEP in response to investigational therapies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22427549      PMCID: PMC3833458          DOI: 10.1167/iovs.11-8475

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  34 in total

1.  Glaucoma detection using scanning laser polarimetry with variable corneal polarization compensation.

Authors:  Robert N Weinreb; Christopher Bowd; Linda M Zangwill
Journal:  Arch Ophthalmol       Date:  2003-02

2.  Sensitivity and specificity of new GDx parameters.

Authors:  Thomas P Colen; Nancy E M L Tang; Paul G H Mulder; Hans G Lemij
Journal:  J Glaucoma       Date:  2004-02       Impact factor: 2.503

3.  Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures.

Authors:  William A Hare; Elizabeth WoldeMussie; Robert N Weinreb; Hau Ton; Guadalupe Ruiz; Mercy Wijono; Barbara Feldmann; Linda Zangwill; Larry Wheeler
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-08       Impact factor: 4.799

4.  Qualitative and quantitative morphologic changes in the vasculature and extracellular matrix of the prelaminar optic nerve head in eyes with POAG.

Authors:  Ozan-Yueksel Tektas; Elke Lütjen-Drecoll; Michael Scholz
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-05-19       Impact factor: 4.799

5.  Experimental glaucoma in the rhesus monkey.

Authors:  D Gaasterland; C Kupfer
Journal:  Invest Ophthalmol       Date:  1974-06

6.  The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.

Authors:  Michael A Kass; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John L Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson; Mae O Gordon
Journal:  Arch Ophthalmol       Date:  2002-06

7.  Scanning laser polarimetry with variable corneal compensation: identification and correction for corneal birefringence in eyes with macular disease.

Authors:  Harmohina Bagga; David S Greenfield; Robert W Knighton
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-05       Impact factor: 4.799

8.  Dendrite plasticity in the lateral geniculate nucleus in primate glaucoma.

Authors:  Tina Ly; Neeru Gupta; Robert N Weinreb; Paul L Kaufman; Yeni H Yücel
Journal:  Vision Res       Date:  2010-08-06       Impact factor: 1.886

9.  Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures.

Authors:  William A Hare; Elizabeth WoldeMussie; Ronald K Lai; Hau Ton; Guadalupe Ruiz; Teresa Chun; Larry Wheeler
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-08       Impact factor: 4.799

10.  Scanning laser polarimetry in monkey eyes using variable corneal polarization compensation.

Authors:  Robert N Weinreb; Christopher Bowd; Linda M Zangwill
Journal:  J Glaucoma       Date:  2002-10       Impact factor: 2.503

View more
  5 in total

1.  The non-human primate experimental glaucoma model.

Authors:  Claude F Burgoyne
Journal:  Exp Eye Res       Date:  2015-06-09       Impact factor: 3.467

2.  Relating Retinal Ganglion Cell Function and Retinal Nerve Fiber Layer (RNFL) Retardance to Progressive Loss of RNFL Thickness and Optic Nerve Axons in Experimental Glaucoma.

Authors:  Brad Fortune; Grant Cull; Juan Reynaud; Lin Wang; Claude F Burgoyne
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-06       Impact factor: 4.799

3.  Neuroprotective Effects of Memantine in the Retina of Glaucomatous Rats: An Electron Microscopic Study.

Authors:  Hande Celiker; Nursen Yuksel; Seyhun Solakoglu; Levent Karabas; Fadime Aktar; Yusuf Caglar
Journal:  J Ophthalmic Vis Res       Date:  2016 Apr-Jun

4.  Exosomes derived from MSCs ameliorate retinal laser injury partially by inhibition of MCP-1.

Authors:  Bo Yu; Hui Shao; Chang Su; Yuanfeng Jiang; Xiteng Chen; Lingling Bai; Yan Zhang; Qiutang Li; Xiaomin Zhang; Xiaorong Li
Journal:  Sci Rep       Date:  2016-09-30       Impact factor: 4.379

Review 5.  Current perspective of neuroprotection and glaucoma.

Authors:  Kailin Tian; Shannon Shibata-Germanos; Milena Pahlitzsch; M Francesca Cordeiro
Journal:  Clin Ophthalmol       Date:  2015-11-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.